Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

UFS outlines research achievements
2011-09-02

 

At the launch of the 2010 Annual Research Report, were from the left: Mr Robert Kriger, the director for Policy and Strategy at the National Research Foundation (NRF); Prof. Driekie Hay, Vice-Rector: Academic and Prof. Frans Swanepoel, Senior Director: Research Development.
Photo: Stephen Collett

The University of the Free State (UFS) is well on course for delivery on its most important academic duty as a research university. This was the message that came forward at the launch of the 2010 Annual Research Report of the UFS on 30 August 2011.

Speakers at the launch, which included Prof. Jonathan Jansen, Vice-Chancellor and Rector, as well as Prof. Driekie Hay, Vice-Rector: Academics outlined the key strategies and achievements of the UFS for the 2010 academic year. This included the establishment of a Postgraduate School at the UFS, the first of its kind at a public university in South Africa. Prof. Hay told guests that the aim of the Postgraduate School was to broaden research and deepens scholarship on postgraduate education in the country. She highlighted some initiatives the UFS undertook in 2010 to build and maintain its intellectual capital. Some of these initiatives included the appointment of seven senior professors and recruiting more female and black scholars and academics.   
Also speaking at the event was Mr Robert Kriger, the director for Policy and Strategy at the National Research Foundation (NRF). Kriger reflected on the brilliant minds of scholars such as Archie Mafeje, Lewis Nkosi and Dennis Brutus and argued for efforts to increase the country’s research output.
Some highlights of the 2010 Annual Research Report:
  • The total funding available for research at the UFS increased from approximately R199 million in 2009 to just over R210 million in 2010. A total of R31.8 million was made available from central university funds.
  • In 2010 the UFS was home to 92 NRF-rated researchers. During 2010, four researchers applied for re-evaluation and of these, two improved their rating, while a further five received a first-time rating.
  • The Faculty of Natural and Agricultural Sciences continue to be the most prolific producer of publications in accredited journals, while the Faculty of Education has shown a 54% increase in its publication output.
  • Staff members in the Physics department at the UFS Qwaqwa Campus published 22 papers in international peer-reviewed journals during 2010.
  • Also at the Qwaqwa Campus: Ms Khethiwe Mtshali,a postgraduate student in the parasitology research unit of the Department of Zoology and Entomology, received a best Honours presenter award at the 1st Annual Research symposium of the National Zoological Gardens of South Africa.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept